

Flow Cytometry Market Size is estimated to reach USD 10.4 Billion by 2031, registering a CAGR of 8.3%

Flow cytometry market report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics.



PORTLAND, OREGON, UNITED STATES, October 7, 2022 /

EINPresswire.com/ -- [Flow cytometry industry](#) generated \$4.7 billion in 2021, and is anticipated to generate \$10.4 billion by 2031, witnessing a CAGR of 8.3% from 2022 to 2031. Technological advancements, high adoption in various research and diagnostic applications, and advent of flow cytometry technology in novel research applications such as cytogenomics, proteomics, and marine biology drive the growth of the global flow cytometry market. However, factors such as high-cost associated with instruments and reagents, lack of awareness among potential end users, and limited availability of technical expertise restrict the market growth. Contrarily, rise in incidences of diseases such as cancer and HIV present new opportunities in the coming years.

□□□□ □□ □□□ □□□□□□□□ :

- Agilent Technologies, Inc.
- Becton Dickinson and Company
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- DiaSorin S.p.A.
- Miltenyi Biotec, Inc.
- Sartorius AG
- Sysmex Corporation
- Thermo Fisher Scientific Inc.

□□□□□□□□ □□□□□□ □□□□□□ <https://www.alliedmarketresearch.com/request-sample/90>

□□□□□□-□□ □□□□□□□□□□:

The outbreak of the Covid-19 pandemic has had a positive impact on the global flow cytometry

market, owing to surge in use of reagents in research activities and clinical trials.

Cytex Biosciences Inc. helped researchers and clinicians in the world to study impact of the COVID-19 virus on human immune systems in March 2020. Flow cytometry showed that COVID-19 patients reduced B-cell and T-cell frequencies as compared to recovered donors and healthy donors.

For more information, please visit <https://www.alliedmarketresearch.com/purchase-enquiry/90>

Based on component, the instruments segment held the highest market share in 2021, accounting for more than half of the global flow cytometry market, and is estimated to maintain its leadership status throughout the forecast period. This is attributed to development of novel instrument designs, demand for highly efficient replaceable components, applications in treatment of newer diseases, and increase in research & developments in flow cytometry techniques. However, the reagents and consumables segment is projected to manifest the highest CAGR of 10.5% from 2022 to 2031, owing to the advantage they offer in flow cytometry analysis.

Based on application, the academic and clinical applications segment accounted for the largest share in 2021, contributing to nearly two-thirds of the global flow cytometry market, and is projected to maintain its lead position during the forecast period. This is attributed to increase in research of academic & clinical applications of flow cytometry. However, the diagnostic segment is expected to portray the largest CAGR of 8.5% from 2022 to 2031, due to rise in use of technology in diagnostic applications.

For more information, please visit:

[Hemophilia Treatment Market](#)

[Mouth Ulcers Treatment Market](#)

For more information, please visit:

David Correa
Allied Analytics LLP
800-792-5285
[email us here](#)

Visit us on social media:

[Facebook](#)
[Twitter](#)
[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/594657824>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.